Preclinical studies suggest that ROR-1 targeted therapies like the use of CAR T and BiTEs, could be effective in treating CLL and Mantle cell lymphoma (MCL) (NCT04763083) [16]. Here, ROR1 is linked to mantle cell lymphoma.